95
Participants
Start Date
April 16, 2019
Primary Completion Date
January 4, 2023
Study Completion Date
January 4, 2023
HPN536 Fixed IV 6 to 560 ng/kg
Fixed dose IV cohorts at doses from 6 to 560 ng/kg
HPN536 1 Prime Step IV 600-1200 ng/kg Target
Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)
2 Prime Step IV 900-14000 ng/kg Target
Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
Memorial Sloan Kettering Cancer Center, New York
Thomas Jefferson University, Philadelphia
University of Virginia Cancer Center, Charlottesville
Mayo Clinic Florida, Jacksonville
Sarah Cannon Research Institute, Nashville
Cleveland Clinic Taussig Cancer Institute, Cleveland
Mayo Clinic Rochester, Rochester
University of Chicago, Chicago
Washington University School of Medicine in St. Louis, St Louis
Stephenson Cancer Center, Oklahoma City
Mary Crowley Cancer Research, Dallas
Mayo Clinic Arizona, Phoenix
University of Southern California, Los Angeles
University of Washington Medical Center, Seattle
University of California Los Angeles, Los Angeles
Massachusetts General Hospital, Boston
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY